Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) Burger, J., Barr, P., Owen, C., Robak, T., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Offner, F., Moreno, C., Dai, S., Szoke, A., Dean, J. P., Kipps, T. J., Ghia, P. CIG MEDIA GROUP, LP. 2021: S316

View details for Web of Science ID 000691910500185